Vivos Therapeutics Inc (VVOS)

Vivos Therapeutics Inc. - A Comprehensive Overview

Please note: Due to limitations in my knowledge cutoff in November 2023, this report will not include information beyond that date.

Company Profile

History and Background:

Vivos Therapeutics, Inc. (VVOS) is a Florida-based medical technology company founded in 2008. It focuses on developing and commercializing innovative technologies for the treatment of obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The company's flagship product is the Vivos System, a non-surgical treatment option that involves reshaping the upper and lower jaws to improve airflow and reduce sleep apnea symptoms.

Core Business Areas:

• Vivos System: This non-surgical treatment involves a series of customized oral appliances that gradually reshape the jaws over time.
• Sleep Diagnostic Services: Vivos offers home sleep tests and in-clinic polysomnography to diagnose OSA and other sleep disorders.
• Dental Sleep Medicine: Vivos collaborates with dental professionals to provide patients with oral appliance therapy and other treatment options for OSA.

Leadership and Corporate Structure:

• President and CEO: Kirk Huntsman
• Chief Medical Officer: Dr. Robert Thornton
• Chief Financial Officer: Brian D. Concannon
• Board of Directors: Robert Silbergleit (Chairman), Charles Patricof, Dr. Thomas Sergott, Michael B. Evans, and Kirk Huntsman.

Top Products and Market Share:

• Vivos System: The primary product generating the majority of the company's revenue.
• Sleep Diagnostic Services: These services support the diagnosis and treatment of OSA and contribute to the overall revenue stream.

Market Share Analysis:

Due to the limitations of my knowledge cutoff in November 2023, I cannot provide a current market share for Vivos Therapeutics. However, the company acknowledges that the OSA market is competitive and several other companies offer alternative treatment options.

Product Performance:

The Vivos System has received positive feedback from patients and healthcare professionals for its effectiveness and non-invasive approach. However, it is important to consider the following:

• Limited long-term studies: The Vivos System is a relatively new technology, and more long-term studies are needed to evaluate its long-term efficacy and safety.
• Compliance challenges: The Vivos System requires patients to wear oral appliances for an extended period, which can be challenging for some individuals.

Total Addressable Market

The global market for OSA treatment was estimated at USD 15.6 billion in 2021 and is projected to reach USD 26.4 billion by 2028, growing at a CAGR of 8.1%. Vivos Therapeutics targets a portion of this market, focusing on patients seeking non-surgical treatment options.

Financial Performance

Note: As my knowledge is limited to November 2023, I cannot provide an updated financial analysis. Nevertheless, here's an overview based on publicly available information:

Revenue: Vivos Therapeutics has experienced revenue growth in recent years, with reported revenue of $14.5 million in 2022.

Profits: The company has not yet achieved profitability, reporting a net loss of $9.4 million in 2022.

Margins: The company's gross margin improved to 80% in 2022, reflecting a focus on cost management.

EPS: Due to the lack of profitability, Vivos Therapeutics does not have earnings per share (EPS).

Cash Flow and Balance Sheet Health: Analyzing the company's cash flow and balance sheet health requires up-to-date information, which I cannot provide due to my knowledge limitations.

Dividends and Shareholder Returns

Vivos Therapeutics does not currently pay dividends and has not historically distributed dividends to shareholders. As a growth company, it reinvests profits for future expansion.

Growth Trajectory

Vivos Therapeutics has experienced revenue growth in recent years, indicating a positive growth trajectory. However, the company's future growth will depend on several factors, including:

• Market adoption of the Vivos System: The company needs to increase awareness and adoption of the Vivos System amongst patients and healthcare providers.
• Reimbursement coverage: The company is working to expand insurance coverage for the Vivos System, which would significantly impact its affordability and accessibility.
• Continued innovation: Vivos needs to continue investing in research and development to improve its existing technologies and develop new treatment options.

Market Dynamics

The OSA treatment market is dynamic and competitive, with various treatment options available, including CPAP, surgery, and oral appliances. Vivos Therapeutics is positioned within the niche market of non-surgical treatment options.

Competitors

Key competitors in the OSA treatment market include:

• ResMed (RMD): Leading manufacturer of CPAP machines and masks.
• Invacare (IVC): Produces a range of respiratory care products, including CPAP machines.
• Align Technology (ALGN): Manufacturer of Invisalign clear aligners, which can be used to treat mild OSA cases.

Vivos Therapeutics differentiates itself from competitors by focusing on non-surgical treatment options.

Potential Challenges and Opportunities

Challenges:

• Market competition: Vivos Therapeutics faces competition from established players in the OSA treatment market.
• Reimbursement challenges: The company needs to secure broader insurance coverage for its Vivos System.
• Limited long-term data: The Vivos System requires more long-term studies to establish its efficacy and safety definitively.

Opportunities:

• Growing market demand: The global market for OSA treatment is expected to continue growing, creating opportunities for Vivos.
• Technological advancements: Vivos can leverage technological advancements to further improve its products and services.
• Strategic partnerships: Partnerships with dental professionals and healthcare providers can expand the company's reach and market access.

Recent Acquisitions (last 3 years)

Based on my knowledge cutoff, I cannot provide information on acquisitions made by Vivos Therapeutics in the last three years.

AI-Based Fundamental Rating:

It is beyond my capabilities to provide an AI-based fundamental rating for Vivos Therapeutics. However, considering the company's current financial health, market position, and future prospects, an analyst might assign a rating between 5 and 7 on a scale of 1 to 10. This rating would reflect the company's potential for growth but also acknowledge the challenges it faces in a competitive market.

Sources and Disclaimers:

This analysis is based on publicly available information as of November 2023. It is essential to consult with financial professionals and conduct thorough research before making investment decisions.

Disclaimer:

This report is for informational purposes only and should not be construed as financial advice. Please consult a qualified financial advisor before making any investment decisions.